ASH 2023 | Exciting updates in CLL: advancing treatment for patients with double-refractory disease
Danielle Brander, MD, Duke University School of Medicine, Durham, NC, briefly discusses exciting updates in chronic lymphocytic leukemia (CLL), highlighting advances being made for patients with double-refractory disease. Dr Brander indicates that effective therapeutics are beginning to emerge for these patients, with longer updates on non-covalent BTK inhibitors such as pirtobrutinib, and novel immunotherapeutic approaches. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Juno/Celgene/BMS: Other: Site PI clinical trial (grant paid to institution, Research Funding; Beigene: Other: Site PI clinical trial (grant paid to institution), Research Funding; MEI Pharma: Other: Site PI clinical trial (grant paid to institution), Research Funding; Ascentage: Other: Site PI clinical trial (grant paid to institution), Research Funding; Novartis: Other: Site PI clinical trial (grant paid to institution), Research Funding; Catapult: Other: Site PI clinical trial (grant paid to institution), Research Funding; DTRM: Other: Site PI clinical trial (grant paid to institution), Research Funding; Pharmacyclics: Consultancy, Other: Site PI clinical trial (grant paid to institution), Research Funding; ArQule/Merck: Other: Site PI clinical trial (grant paid to institution), Research Funding; AstraZeneca/Acerta: Other: Site PI clinical trial (grant paid to institution), Research Funding; NeWave: Other: Site PI clinical trial (grant paid to institution), Research Funding; AbbVie: Consultancy, Other: Site PI clinical trial (grant paid to institution), Research Funding; Genentech: Consultancy, Other: Site PI clinical trial (grant paid to institution), Research Funding; TG Therapeutics: Other: Site PI clinical trial (grant paid to institution), Research Funding; Pharmacyclics: Other: Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for NCCN panel member CLL/SLL and HCL, informCLL registry steering committee; AbbVie: Other: Core registry steering committee ; CLL Society: Other: Alliance in Clinical Trials: Leukemia committee member & Trial Champion of S1925 .
